BioNTech to Acquire CureVac in Strategic mRNA Expansion

CureVac ( (CVAC) ) has shared an announcement.

On June 12, 2025, BioNTech announced its strategic acquisition of CureVac through a public exchange offer, aiming to strengthen its mRNA-based cancer immunotherapy capabilities. This all-stock transaction, supported by major stakeholders, is expected to enhance BioNTech’s research and manufacturing capabilities, creating long-term value for shareholders and advancing the development of transformative cancer treatments.

The most recent analyst rating on (CVAC) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.

Spark’s Take on CVAC Stock

According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.

CureVac’s stock score is driven by its strong financial performance and positive technical indicators. The company’s strategic collaborations and pipeline advancements add value, though operational restructuring and past financial volatility pose risks. The stock’s undervaluation enhances its attractiveness in the biotechnology sector.

To see Spark’s full report on CVAC stock, click here.

More about CureVac

CureVac is a multinational biotech company founded in 2000, specializing in the development of messenger RNA (mRNA) technology for human medicine. The company focuses on creating mRNA therapeutics that enhance immune responses at lower doses, with applications in infectious diseases and oncology.

Average Trading Volume: 654,419

Technical Sentiment Signal: Buy

Current Market Cap: $961.4M

For an in-depth examination of CVAC stock, go to TipRanks’ Overview page.